Core Viewpoint - The approval of the raw material drug cytidine diphosphate choline by the National Medical Products Administration marks a significant milestone for the company, enhancing its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Xinxiang Pharmaceutical, received the "Approval Notification for Chemical Raw Material Drug Listing Application" for cytidine diphosphate choline [1] - This approval indicates that the product meets national drug review technical standards and has passed GMP compliance checks [1] Group 2: Product Significance - Cytidine diphosphate choline is commonly used as a neuroprotective agent and brain metabolism activator, with its core pharmacological action being the improvement of brain function and promotion of nerve repair [1] - The clinical application range includes patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases [1] Group 3: Market Impact - The approval will effectively broaden the company's product line and enhance its market competitiveness in the active pharmaceutical ingredient sector [1]
拓新药业：胞磷胆碱原料药获上市批准